Results 11 to 20 of about 790,096 (261)

Fate and removal of pharmaceuticals during sewage treatment [PDF]

, 2005
Pharmaceuticals, personal care products and their metabolites are continuously entering the environment through many routes, especially from the effluent of sewage treatment plants.
Thompson, Andrew
core   +7 more sources

Japanese regulation of biosimilar products: past experience and current challenges

British Journal of Clinical Pharmacology, 2016
Teruyo Arato
exaly   +2 more sources

Informing Patients about Biosimilar Medicines: The Role of European Patient Associations

Pharmaceuticals, 2021
Biosimilar medicines support the sustainability of national healthcare systems, by reducing costs of biological therapies through increased competition.
Y. Vandenplas, S. Simoens, P. VanWilder, A. Vulto, I. Huys   +4 more
semanticscholar   +1 more source

Innovator Versus Biosimilar Ranibizumab in Polypoidal Choroidal Vasculopathy: Real-World Evidence

Ophthalmology and Therapy, 2022
To analyze the efficacy and safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India; BRm; Razumab®) and the innovator ranibizumab drug (IRm; LUCENTIS®) in Indian patients with polypoidal ...
Manoj Soman, Indu J. Nair, J. Sheth, Unnikrishnan Nair   +3 more
semanticscholar   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Pharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
M. García-Goñi, Isabel Río‐Álvarez, D. Carcedo, A. Villacampa   +3 more
semanticscholar   +1 more source

Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases

Ophthalmology and Therapy, 2021
To assess the safety profile of the intravitreal ranibizumab biosimilar molecule, Razumab® (Intas Pharmaceuticals, Ahmedabad, India) in chorioretinal disorders under real-world conditions. This was a multicenter, retrospective chart review which included
D. Chakraborty, M. W. Stewart, J. Sheth, T. Sinha, S. Boral, A. Das, S. Mondal, Angshuman Mukherjee   +7 more
semanticscholar   +1 more source

Portuguese Position Paper on the Use of Biosimilars in Psoriasis

Acta Médica Portuguesa, 2016
Keywords: Biological Agents; Biosimilar Pharmaceuticals; Portugal; Psoriasis/drug therapy.
Tiago Torres, Ana Ferreira, Paulo Ferreira, Martinha Henriques, Luiz Leite, Sofia Magina, Gabriela Marques Pinto, Hugo Oliveira, Artur Sousa Basto, Rui Tavares Bello, Paulo Varela, Antonio Massa, Manuela Selores, Paulo Filipe, On behalf of The Portuguese College of Dermatology, On behalf of The Portuguese Society of Dermatology and Venereology   +15 more
doaj   +1 more source

Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis

Systematic Reviews, 2021
Background Biologic drugs such as adalimumab, etanercept, and infliximab represent major first-line and second-line treatments for rheumatoid arthritis (RA) patients. However, their high cost poses a massive burden on healthcare systems worldwide.
Bruna O. Ascef, Matheus O. Almeida, Ana Cristina de Medeiros Ribeiro, Danieli C. O. Andrade, Haliton A. de Oliveira Júnior, Tiago V. Pereira, Patrícia C. de Soárez   +6 more
doaj   +1 more source

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? [PDF]

The European Journal of Health Economics, 2013
Biological medicines contain a biological substance that is produced by or derived from a living organism. The active substances of biologicals are usually larger and more complex than those of chemically derived medicines (non-biological medicine). Biologicals are used for the treatment of chronic and life-threatening diseases such as cancer, multiple
Farfan-Portet, María-Isabel, Gerkens, Sophie, Lepage-Nefkens, Isabelle, Vinck, Irmgard, Hulstaert, Frank   +4 more
openaire   +2 more sources

Knowledge and Viewpoints on Biosimilar Monoclonal Antibodies among Asian Physicians: Comparison with European Physicians

The Korean Journal of Gastroenterology, 2019
Background/Aims: Current knowledge and viewpoints regarding biosimilars among physicians in Asia are unknown, even though these were investigated by European Crohn’s and Colitis Organization (ECCO) members in 2013 and 2015.
Soo-Kyung Park, Won Moon, Eun Soo Kim, Sang Hyun Park, Dong Il Park   +4 more
doaj   +1 more source